510 related articles for article (PubMed ID: 23499529)
41. Downstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-Sulfotransferase.
Thieker DF; Xu Y; Chapla D; Nora C; Qiu H; Felix T; Wang L; Moremen KW; Liu J; Esko JD; Woods RJ
Sci Rep; 2018 Aug; 8(1):11832. PubMed ID: 30087361
[TBL] [Abstract][Full Text] [Related]
42. Influence of saccharide modifications on heparin lyase III substrate specificities.
Wu J; Chopra P; Boons GJ; Zaia J
Glycobiology; 2022 Mar; 32(3):208-217. PubMed ID: 33822051
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
44. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells.
Savion N; Disatnik MH; Nevo Z
J Cell Physiol; 1987 Jan; 130(1):77-84. PubMed ID: 3805131
[TBL] [Abstract][Full Text] [Related]
45. Human heparanase nuclear localization and enzymatic activity.
Schubert SY; Ilan N; Shushy M; Ben-Izhak O; Vlodavsky I; Goldshmidt O
Lab Invest; 2004 May; 84(5):535-44. PubMed ID: 15034597
[TBL] [Abstract][Full Text] [Related]
46. Biosynthesis of 3-O-sulfated heparan sulfate: unique substrate specificity of heparan sulfate 3-O-sulfotransferase isoform 5.
Chen J; Duncan MB; Carrick K; Pope RM; Liu J
Glycobiology; 2003 Nov; 13(11):785-94. PubMed ID: 12907690
[TBL] [Abstract][Full Text] [Related]
47. Molecular structure of heparan sulfate from Spalax. Implications of heparanase and hypoxia.
Sandwall E; Bodevin S; Nasser NJ; Nevo E; Avivi A; Vlodavsky I; Li JP
J Biol Chem; 2009 Feb; 284(6):3814-22. PubMed ID: 19068480
[TBL] [Abstract][Full Text] [Related]
48. Characterizing the non-reducing end structure of heparan sulfate.
Wu ZL; Lech M
J Biol Chem; 2005 Oct; 280(40):33749-55. PubMed ID: 16079142
[TBL] [Abstract][Full Text] [Related]
49. Chemoenzymatic design of heparan sulfate oligosaccharides.
Liu R; Xu Y; Chen M; Weïwer M; Zhou X; Bridges AS; DeAngelis PL; Zhang Q; Linhardt RJ; Liu J
J Biol Chem; 2010 Oct; 285(44):34240-9. PubMed ID: 20729556
[TBL] [Abstract][Full Text] [Related]
50. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.
Casu B; Naggi A; Torri G
Matrix Biol; 2010 Jul; 29(6):442-52. PubMed ID: 20416374
[TBL] [Abstract][Full Text] [Related]
51. [Human heparanase: roles in invasion and metastasis of cancer].
Gohji K; Katsuoka Y; Okamoto M; Kamidono S; Kitazawa S; Toyoshima M; Dong J; Nakajima M
Hinyokika Kiyo; 2000 Oct; 46(10):757-62. PubMed ID: 11215206
[TBL] [Abstract][Full Text] [Related]
52. Use of biosynthetic enzymes in heparin and heparan sulfate synthesis.
Chappell EP; Liu J
Bioorg Med Chem; 2013 Aug; 21(16):4786-92. PubMed ID: 23313092
[TBL] [Abstract][Full Text] [Related]
53. Preparation of heparan sulfate-like polysaccharide and application in stem cell chondrogenic differentiation.
Zhao S; Wang Z; Chen J; Chen J
Carbohydr Res; 2015 Jan; 401():32-8. PubMed ID: 25464079
[TBL] [Abstract][Full Text] [Related]
54. Participation of syndecan 2 in the induction of stress fiber formation in cooperation with integrin alpha5beta1: structural characteristics of heparan sulfate chains with avidity to COOH-terminal heparin-binding domain of fibronectin.
Kusano Y; Oguri K; Nagayasu Y; Munesue S; Ishihara M; Saiki I; Yonekura H; Yamamoto H; Okayama M
Exp Cell Res; 2000 May; 256(2):434-44. PubMed ID: 10772816
[TBL] [Abstract][Full Text] [Related]
55. Reduction of anionic sites in the glomerular basement membrane by heparanase does not lead to proteinuria.
van den Hoven MJ; Wijnhoven TJ; Li JP; Zcharia E; Dijkman HB; Wismans RG; Rops AL; Lensen JF; van den Heuvel LP; van Kuppevelt TH; Vlodavsky I; Berden JH; van der Vlag J
Kidney Int; 2008 Feb; 73(3):278-87. PubMed ID: 18046314
[TBL] [Abstract][Full Text] [Related]
56. Irreversible glucuronyl C5-epimerization in the biosynthesis of heparan sulfate.
Hagner-McWhirter A; Li JP; Oscarson S; Lindahl U
J Biol Chem; 2004 Apr; 279(15):14631-8. PubMed ID: 14718527
[TBL] [Abstract][Full Text] [Related]
57. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
58. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.
Vlodavsky I; Ilan N; Naggi A; Casu B
Curr Pharm Des; 2007; 13(20):2057-73. PubMed ID: 17627539
[TBL] [Abstract][Full Text] [Related]
59. An Overview of the Structure, Mechanism and Specificity of Human Heparanase.
Wu L; Davies GJ
Adv Exp Med Biol; 2020; 1221():139-167. PubMed ID: 32274709
[TBL] [Abstract][Full Text] [Related]
60. Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate.
Sasaki N; Higashi N; Taka T; Nakajima M; Irimura T
J Immunol; 2004 Mar; 172(6):3830-5. PubMed ID: 15004189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
